An anti-eCIRP strategy for necrotizing enterocolitis.

Colleen P NofiJose M PrinceMariana R BrewerMonowar AzizPing Wang

Published in: Molecular medicine (Cambridge, Mass.) (2024)

eCIRP exacerbates NEC evidenced by protection with CIRP-deficiency and administration of MOP3, a CIRP-directed therapeutic, in a murine model. Thus, eCIRP is a novel target with human relevance, and MOP3 is a promising treatment for lethal NEC.

Keyphrases

endothelial cells
replacement therapy
low birth weight
combination therapy
preterm infants